Vifor International AG (CSL Vifor)

Sep 26, 2025

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

May 23, 2025

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

Sep 24, 2024

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

Apr 24, 2024

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Mar 28, 2024

Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients

Mar 19, 2024

Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure